ROIV insider filings
Roivant Sciences Ltd. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen ROIV transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 41 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 41 legs across 14 filings by 7 insiders — 5,681,029 shares, $218,618,863 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 73.
- Largest priced transaction: sale of 550,280 shares @ $39.17 ($21,554,468) by MANCHESTER KEITH S, filed 2026-11-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Gold Daniel Allen — Director | 3 | — | 7 legs · 1,381,762 sh · $53,536,738 | 6 |
| MANCHESTER KEITH S — Director | 2 | — | 7 legs · 1,381,762 sh · $53,536,738 | 5 |
| QVT Financial LP | 1 | — | 7 legs · 1,381,762 sh · $53,536,738 | 3 |
| Venker Eric — President & Immunovant CEO | 7 | — | 9 legs · 1,187,943 sh · $43,697,134 | 5 |
| Pulik Richard — CFO | 3 | — | 4 legs · 300,000 sh · $12,473,272 | 6 |
| Fitzgerald Meghan — Director | 4 | — | 3 legs · 25,112 sh · $1,001,152 | 5 |
| Epperly Melissa B, — Director | 5 | — | 4 legs · 22,688 sh · $837,091 | 7 |
| Gline Matthew — CEO, Director | 3 | — | — | 9 |
| Sukhatme Mayukh — President & CIO, Director | 3 | — | — | 9 |
| Torti Frank — President and Vant Chair | 2 | — | — | 8 |
+4 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Roivant Sciences Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 3 | Hammerbacher Jeffrey Evan — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-18 | 4 | MANCHESTER KEITH S — Director | Sale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 more | EDGAR |
| 2026-11-18 | 4 | Gold Daniel Allen — Director | Sale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 more | EDGAR |
| 2026-11-18 | 4 | QVT Financial LP | Sale (S): 79,461 @ $39.17 · Sale (S): 550,280 @ $39.17 · Sale (S): 18,927 @ $38.99 · Sale (S): 131,073 @ $38.99 · Other (J): 2,635,169 @ $0 · Other (J): 15,969 @ $0 · +4 more | EDGAR |
| 2026-11-12 | 4 | Torti Frank — President and Vant Chair | Other (J): 173,683 @ $40.43 · Other (J): 218,369 @ $41.13 · Other (J): 240,755 @ $41.63 · Other (J): 151,293 @ $42.01 · Other (J): 329,550 @ $40.36 · Other (J): 62,493 @ $41.13 · +1 more | EDGAR |
| 2026-11-12 | 4 | Gline Matthew — CEO, Director | Other (J): 25,841 @ $40.43 · Other (J): 32,490 @ $41.13 · Other (J): 30,083 @ $41.63 · Other (J): 18,905 @ $42.01 · Other (J): 41,179 @ $40.36 · Other (J): 7,809 @ $41.13 · +1 more | EDGAR |
| 2026-11-12 | 4 | Sukhatme Mayukh — President & CIO, Director | Other (J): 26,152 @ $40.43 · Other (J): 32,882 @ $41.13 · Other (J): 32,672 @ $41.63 · Other (J): 20,533 @ $42.01 · Other (J): 44,723 @ $40.36 · Other (J): 8,482 @ $41.13 · +1 more | EDGAR |
| 2026-11-12 | 4 | Venker Eric — President & Immunovant CEO | Sale (S): 158,194 @ $40.44 · Sale (S): 29,749 @ $41 | EDGAR |
| 2026-11-12 | 4 | Pulik Richard — CFO | Option exercise (M): 125,000 @ $3.85 · Sale (S): 125,000 @ $41.20 · Option exercise (M): 127,365 @ $3.85 · Sale (S): 45,195 @ $41.47 · Sale (S): 82,170 @ $42.03 · Sale (S): 47,635 @ $41.89 · +2 more | EDGAR |
| 2026-11-05 | 4 | Venker Eric — President & Immunovant CEO | Sale (S): 200,000 @ $36.31 | EDGAR |
| 2026-10-30 | 4 | Venker Eric — President & Immunovant CEO | Sale (S): 200,000 @ $36.59 | EDGAR |
| 2026-10-27 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 383 @ $0 · Tax withholding (F): 77 @ $36.49 | EDGAR |
| 2026-10-27 | 4 | Epperly Melissa B, — Director | Grant/award (A): 513 @ $0 · Tax withholding (F): 116 @ $36.49 | EDGAR |
| 2026-10-27 | 4 | Oren Ilan — Director | Grant/award (A): 810 @ $0 | EDGAR |
| 2026-10-22 | 4 | Venker Eric — President & Immunovant CEO | Sale (S): 185,856 @ $35.09 · Sale (S): 14,144 @ $35.42 | EDGAR |
| 2026-10-20 | 4 | Gline Matthew — CEO, Director | Tax withholding (F): 34,638 @ $33.53 | EDGAR |
| 2026-10-20 | 4 | Sukhatme Mayukh — President & CIO, Director | Tax withholding (F): 19,976 @ $33.53 | EDGAR |
| 2026-10-05 | 4 | Epperly Melissa B, — Director | Option exercise (M): 17,750 @ $4.46 · Sale (S): 16,850 @ $36.08 · Sale (S): 900 @ $36.57 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-10-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 40,309 @ $36.57 | EDGAR |
| 2026-10-02 | 4 | Gline Matthew — CEO, Director | Tax withholding (F): 76,171 @ $36.57 | EDGAR |
| 2026-10-02 | 4 | Sukhatme Mayukh — President & CIO, Director | Tax withholding (F): 46,879 @ $36.57 | EDGAR |
| 2026-10-02 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $36.62 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-09-22 | 4 | Humes Jennifer — Chief Accounting Officer | Tax withholding (F): 3,880 @ $39.77 | EDGAR |
| 2026-09-22 | 4 | Pulik Richard — CFO | Tax withholding (F): 2,129 @ $39.77 | EDGAR |
| 2026-09-18 | 4 | MANCHESTER KEITH S — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Gold Daniel Allen — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Oren Ilan — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Epperly Melissa B, — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Fitzgerald Meghan — Director | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Epperly Melissa B, — Director | Sale (S): 4,338 @ $39.65 · Sale (S): 600 @ $40.38 | EDGAR |
| 2026-09-17 | 4 | Fitzgerald Meghan — Director | Sale (S): 4,712 @ $39.68 · Sale (S): 400 @ $40.45 | EDGAR |
| 2026-09-14 | 4 | Gold Daniel Allen — Director | Tax withholding (F): 5,133 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Oren Ilan — Director | Tax withholding (F): 2,378 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Epperly Melissa B, — Director | Tax withholding (F): 2,179 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | Fitzgerald Meghan — Director | Tax withholding (F): 1,743 @ $40.94 | EDGAR |
| 2026-09-14 | 4 | MOMTAZEE JAMES C — Director | Tax withholding (F): 2,905 @ $40.94 | EDGAR |
| 2026-09-10 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 20,000 @ $8.80 · Sale (S): 20,000 @ $39.90 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 166,182 @ $35.63 · Sale (S): 33,818 @ $36.44 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | Pulik Richard — CFO | Tax withholding (F): 5,749 @ $36.84 | EDGAR |
| 2026-08-24 | 4 | Venker Eric — President & Immunovant CEO | Tax withholding (F): 13,909 @ $36.84 | EDGAR |
| 2026-08-21 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 172,899 @ $3.85 · Sale (S): 172,899 @ $37.17 · Option exercise (M): 17,519 @ $3.85 · Sale (S): 17,519 @ $37.30 · Option exercise (M): 144,756 @ $3.85 · Sale (S): 144,756 @ $36.48 · +3 more | EDGAR |
| 2026-08-18 | 4 | Sukhatme Mayukh — President & CIO, Director | Option exercise (M): 243,177 @ $3.85 · Sale (S): 243,177 @ $36.23 · Option exercise (M): 284,707 @ $3.85 · Sale (S): 284,707 @ $36.25 · Option exercise (M): 105,141 @ $3.85 · Sale (S): 105,141 @ $36.59 · +5 more | EDGAR |
| 2026-07-29 | 4 | Venker Eric — President & Immunovant CEO | Option exercise (M): 200,000 @ $3.85 · Sale (S): 200,000 @ $34.95 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Epperly Melissa B, — Director | Grant/award (A): 543 @ $0 | EDGAR |
| 2026-07-21 | 4 | Oren Ilan — Director | Grant/award (A): 775 @ $0 | EDGAR |
| 2026-07-21 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 405 @ $0 | EDGAR |
| 2026-07-02 | 4 | Torti Frank — President and Vant Chair | Tax withholding (F): 40,310 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Sukhatme Mayukh — President & CIO, Director | Tax withholding (F): 46,878 @ $35.39 | EDGAR |
| 2026-07-02 | 4 | Fitzgerald Meghan — Director | Option exercise (M): 10,000 @ $8.80 · Sale (S): 10,000 @ $34.90 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Roivant Sciences Ltd.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-21 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
GET https://api.filingpulse.io/v1/insider-trades?ticker=ROIV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs